The 8p11 myeloproliferative syndrome (EMS) is associated with translocations that disrupt the FGFR1 gene. To date, eight fusion partners of FGFR1 have been identified. However, no primary leukemia cell lines were identified that contain any of these fusions. Here, we screened over 40 acute myeloid leukemia cell lines for constitutive 
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Abstract
The 8p11 myeloproliferative syndrome (EMS) is associated with translocations that disrupt the FGFR1 gene. To date, eight fusion partners of FGFR1 have been identified.
However, no primary leukemia cell lines were identified that contain any of these fusions. Here, we screened over 40 acute myeloid leukemia cell lines for constitutive phosphorylation of STAT5 and applied an immunoaffinity profiling strategy to identify 
Introduction
Disruption of fibroblast growth factor receptor-1 (FGFR1) gene is associated with a disease entity known as the 8p11 myeloproliferative syndrome (EMS)/stem cell leukemia-lymphoma syndrome. It is characterized by myeloid hyperplasia that rapidly transforms to acute myelogenous leukemia and/or lymphoma within a year of original diagnosis 
Study Design
Cell Culture
The KG-1 cell line was obtained from DSMZ. The KG-1a cell line was obtained from ATCC. All cell lines were grown in RPMI-1640 medium with 10% FBS.
Phosphopeptide immunoprecipitation
Phosphopeptides were prepared using the PhosphoScan® Kit (Cell Signaling Technology).
Analysis by LC-MS/MS Mass Spectrometry
Analysis was performed as previously described 14 .
siRNA and siRNA transfection 
Rapid Amplification of Complementary DNA Ends
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From RNeasy Mini Kit (Qiagen) was used to extract RNA from human leukemia cell lines.
Rapid amplification of cDNA ends was performed with the use of 5' RACE system (Invitrogen) with primers FGFR1-P1 (5'-ATGGACAGGTCCAGGTACTCC) for cDNA synthesis and FGFR1-P2 (5'-ACTCTGGTGGGTGTAGATCCG) and FGFR1-P3 (5'-CTTGGAGGCATACTCCACGAT) for a nested PCR reaction.
RT-PCR Assay
For RT-PCR, first-strand cDNA was synthesized from 2.5 µg of total RNA with the use of SuperScript TM III first-strand synthesis system (Invitrogen) with oligo (dT) 20 . Then, 
Western blotting
Cells were lysed in 1x cell lysis buffer (Cell Signaling Technology) supplemented with Protease Arrest TM (G Biosciences) and separated by electrophoresis. All antibodies and reagents for immunoblotting were from Cell Signaling Technology.
For
Results and Discussion
Activated tyrosine kinases are frequently involved in various malignancies including acute myeloid leukemia (AML). They phosphorylate and activate STAT5, which plays an important role in leukemogenesis 15 . We screened over 40 AML cell lines for 
fusion-mediated signaling pathways. Indeed, this phosphoproteomic analysis provides the most comprehensive tyrosine phosphorylation signaling profile reported for FGFR1 fusions to date. In our study, we observed tyrosine phosphorylation of known downstream effectors of FGFR1 (Figure 2A ) 19, 20 . Notably, PLCγ1 plays an important role in FGFR1 fusion mediated EMS in vivo 12 . Here, we confirmed the tyrosine phosphorylation of PLCγ1 at multiple sites, including several novel sites (Y379, 481, 506, and 977). Moreover, we identified many novel tyrosine phosphorylated proteins that could be regulated by FGFR1 fusions. SHIP1 is a hematopoietic-specific phosphatase that regulates cell survival, growth, cell cycle arrest, and apoptosis 21 . We
show that phosphorylation of SHIP1 at tyrosine 1020 is inhibited by siRNA against FGFR1 (Figure 2A ), suggesting that SHIP1 could be a novel downstream target of the FGFR1 fusion. This information may be useful to develop novel therapeutic approaches for the effective treatment of acute myeloid leukemia containing FGFR1 fusions, as well as other human disorders associated with deregulated FGFR1 activity 22, 23 . For personal use only. on . by guest www.bloodjournal.org From
(B)
Electroporation with FGFR1 siRNA into KG-1 cells resulted in a decrease of proliferation and (C) an increase in apoptosis.
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